Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data

Calgary, Canada (ots/PRNewswire) - Resverlogix Corp.
(TSX:RVX) announced today that it will host a live teleconference and
webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00 am
Mountain time. The purpose of the teleconference is to discuss the
top line results of the Company's Phase 1b/2a clinical trial for
RVX-208, an oral small molecule in development to treat
atherosclerosis and cardiovascular disease.

The dial-in numbers for this event are toll free 1-800-319-4610
and international 1-604-638-5340. A link for this webcast will be
posted onto the homepage of Resverlogix's website and can be accessed
from the following address
http://services.choruscall.com/links/resverlogix090928.html.

The webcast will be available on the Resverlogix website for
replay for a period of 45 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) PR program is
the Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as Acute
Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery
Disease and other vascular disorders. Resverlogix Corp. trades on the
Toronto Stock Exchange (TSX:RVX). For further information please
visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; US Investor
Relations: Susan Noonan, Managing Partner, S.A. Noonan
Communications, LLC, Phone: +1-212+966-3650, Email:
susan@sanoonan.com; US Media Relations: Eric Goldman, Vice President,
Rx Communications Group, Phone: +1-917-322-2563, Email:
egoldman@rxir.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications,
Resverlogix Corp., Phone: +1-604-538-7072, Fax: +1-403-256-8495,
Email:
Theresa@resverlogix.com; US Investor Relations: Susan Noonan,
Managing
Partner, S.A. Noonan Communications, LLC, Phone: +1-212+966-3650,
Email:
susan@sanoonan.com; US Media Relations: Eric Goldman, Vice President,
Rx
Communications Group, Phone: +1-917-322-2563, Email:
egoldman@rxir.com